How To Test For Platelet Function

Size: px
Start display at page:

Download "How To Test For Platelet Function"

Transcription

1 Platelet function in thrombocytopenia Mark Roest Synapse Research Institute, Maastricht

2 No Disclosures

3 Trauma

4 1. Adhesion

5 2. Activation and Aggregation

6 3. Stable Aggregate Formation

7 4. Repair

8 Platelet Disorder Mucocutaneous bleeding low platelet count and/or dysfunction epistaxis Prolonged bleeding Heavy Bruising Petechiae Gastro-intestinal bleeding Oral bleeding Bleeding after tooth extraction Menorrhagia

9 Thrombocytopenia: Current guidelines Platelet counts < 10*10 9 platelets / L transfusion Platelet counts > 10*10 9 platelets / L no transfusion We need platelet function testing in addition to platelet counts Those patients don t need transfusion if the function of the remaining platelets is still adequate Those patients need transfusion if the function of the remaining platelets is not adequate

10 Platelet function monitoring in diagnostic settings Bleeding time PFA-100 ROTEM TEG verifynow multiplate LTA These tests are based on platelet aggregation or platelet deposition This is highly dependent on platelete concentration

11 Platelet function tests Bleeding Time and PFA: Only for VW diseases and platelet adhesion ROTEM: Only for prediction post surgery bleeding? VASP: Only for P2Y12 inhibitor monitoring VerifyNOW: Only for P2Y12 inhibitors and aspirin monitoring Multiplate: Potentially interesting no progression Aggregometry: Gold standard disappearing Whole blood platelet function flow cytometry

12 SSC Count Count Platelet Function Agonist Anti-P-selectin P-selectine αiibβ Anti-fibrinogeen FSC CD62P-PE CD62P-PE

13 Platelet Activation Test (PACT) TRAP ADP Thrombin receptor (PAR1) ADP receptor (P 2 Y 12 ) Blood Platelet Collagen receptor (GPVI) CRP P-selectin (MFI) Flow Cytometry ADP ( TRAP ( M) CRP(ng/mL) P-selectin (MFI) Master Mix P-selectin (MFI)

14 Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia

15 Platelet Function in stored concentrates (1) P-selectin expression Day Time Days Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion Aug;53(8):

16 Platelet Function in stored concentrates (2) Time Days Cécile H. Kicken, Mark Roest, Yvonne M. Henskens, Bas de Laat, Dana Huskens. Monitoring platelet concentrates, submited

17 Platelet Function in stored concentrates (3) Time Days P-selectin expression (AU) SFLLRN Day a IIb b 3 activation (AU) SFLLRN Day P-selectin expression (AU) CRP Day a IIb b 3 activation (AU) CRP Day P-selectin expression (AU) ADP Day a IIb b 3 activation (AU) ADP Day P-selectin expression (AU) U Day a IIb b 3 activation (AU) U Day Roest M, van Holten TC, Fleurke GJ, Remijn JA. Platelet Activation Test in Unprocessed Blood (Pac-t-UB) to Monitor Platelet Concentrates and Whole Blood of Thrombocytopenic Patients. Transfus Med Hemother Apr;40(2):

18 Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia

19 Platelet function in blood of patients with thrombocytopenia Healthy controls (n=10) Patients with thrombocytopenia (n=11) Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion May;56(5):

20 P -s e le c tin e x p re s s io n (% ) P A R - 1 P A R - 4 C R P A D P P la te le t c o u n t (x /L ) Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited

21 Platelet function pre- and post-transfusion Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion May;56(5):

22 M F I P -s e le c tin (u n its ) Platelet function, platelet count and bleeding risk Platelet function and bleeding Platelet count and bleeding P A R 1 -A P P A R 4 -A P * M F I P -s e le c tin (u n its ) ** 0 0 N o B le e d in g B le e d in g N o B le e d in g B le e d in g Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited

23 ITP Auto-antibodies to platelets Increased Platelet Consumption Low Platelet Counts ITP has a heterogeneous pathogenesis and the phenotype does not necessarily correlate with platelet counts Platelet Function Testing to customize the therapy?

24 Platelet function testing in ITP van Bladel, Laarhoven AG, van der Heijden LB, Heitink-Pollé KM, Porcelijn L, van der Schoot CE, de Haas M, Roest M, Vidarsson G, de Groot PG, Bruin MCFunctional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014;123:

25 Conclusion PACT can be used to monitor platelet function in concentrates PACT can be used to measure platelet function in thrombocytopenia Upcoming studies will show if this test can be used to customize the treatment of patients with thrombocytopenia

26 Mark Roest Philip de Groot Dana Huskens Bas de Laat Rob Fijnheer Leonie Boven Esther van Bladel Birol Batman Rolf Urbanus Suzanne Korporaal Albert Huisman Angela Bikker Jaap Jan Zwaginga Rutger Middelburg Jasper Remijn

Platelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Platelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,

More information

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University Platelet storage pool disease case discussions Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University Case I 29 yo WF presented for evaluation of possible platelet storage pool disease,

More information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and

More information

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the

More information

Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )

Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Multiplate platelet function analysis in whole blood based on impedance aggregometry Multiplate instrument 5 channels for

More information

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015 Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic looks at hereditary platelet

More information

Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing

Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing Paul Harrison Oxford Haemophilia & Thrombosis Centre Churchill Hospital Oxford, UK 10 th February 2011 Namur

More information

Evaluation of the Patient with Suspected Platelet Refractory State

Evaluation of the Patient with Suspected Platelet Refractory State Evaluation of the Patient with Suspected Platelet Refractory State NOTE: While evaluating the patient for suspected immune refractory state provide ABO matched platelets if available. 1. Determine if the

More information

Hemostasis analyzer system

Hemostasis analyzer system Hemostasis analyzer system Providing fast, actionable results to help you reduce risks, complications and costs Get the whole picture with TEG Hemostasis analyzer system For more than forty years, hospitals

More information

Multiplate platelet function analysis - application and interpretation

Multiplate platelet function analysis - application and interpretation Dr. Andreas Calatzis PD Dr. Michael Spannagl Department for Haemostasis and Transfusion Medicine Munich University Clinic Ludwig-Maximilians University Ziemssen Str. 1 80336 Munich, Germany calatzis@haemostasis.de

More information

Rational for secondary prophylaxis in VWD

Rational for secondary prophylaxis in VWD Rational for secondary prophylaxis in VWD Susan Halimeh Medical Thrombosis and Haemophilia treatment Center, Duisburg, Germany Dr. med. Susan Halimeh When is prophylaxis in patients with VWD recommended?

More information

Embedding Point of Care monitoring (ROTEM) in daily practice

Embedding Point of Care monitoring (ROTEM) in daily practice Embedding Point of Care monitoring (ROTEM) in daily practice Yvonne Henskens Clinical chemist Head of unit General Hematology, Hemostasis and Transfusion Central Diagnostic Laboratory Road to ROTEM 2009

More information

Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding.

Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding. Learning Objectives Qualitative and Quantitative Platelet isorders Jeffrey S. Jhang, M.. Assistant Professor of Clinical Pathology College of Physicians and Surgeons New York, New York Understand the evaluation

More information

Point-of-care testing Thrombelastography and platelet transfusion

Point-of-care testing Thrombelastography and platelet transfusion Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria Trauma-induced coagulopathy

More information

Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease

Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease Review of Clinical Signs Series Editor: Bernard M. Karnath, MD Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease Bernard M. Karnath, MD Achief complaint of easy bruising and

More information

Role of Platelets in Haemostasis and Thrombosis

Role of Platelets in Haemostasis and Thrombosis Role of Platelets in Haemostasis and Thrombosis Role of Platelets in Haemostasis and Thrombosis 1. Patient platelet GPVI deficiency Divergence of pathways leading from GPVI to (a) aggregation or (b) ectodomain

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

An Introduction to the Improved FDA Prescription Drug Labeling

An Introduction to the Improved FDA Prescription Drug Labeling An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k103555 B. Purpose for Submission: New submission C. Measurand: Platelet aggregation D. Type of Test: Platelet aggregometer

More information

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. INDEX Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Acquired bleeding disorders, 37-57 acquired combined inhibitor to factor V and thrombin, 55 acquired

More information

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D. Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University

More information

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function

Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function British Committee for Standards in Haematology Writing group: Paul Harrison 1, Ian Mackie 2, Andrew Mumford 3, Carol

More information

Annals of West University of Timisoara

Annals of West University of Timisoara Annals of West University of Timisoara Series of Chemistry 20 (1) (2011) 47-58 LABORATORY TESTING OF PLATELET FUNCTION BY AGGREGOMETRY: WHAT TEST SHOULD BE USED? Daniela Maximov a, Alina Lupu a, Cristiana

More information

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban

More information

Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods

Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods Blood Products Advisory Committee, March 9, 2006 Steven Kleinman, MD Senior Medical Advisor, AABB Co-chair, AABB

More information

Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field

Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field Coagulation and Transfusion Medicine / PLATELET FUNCTION TESTING Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field Lan Zhou,

More information

Recommendations: Other Supportive Therapy of Severe Sepsis*

Recommendations: Other Supportive Therapy of Severe Sepsis* Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial

More information

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,

More information

Management of the new antiplatelets and anticoagulants

Management of the new antiplatelets and anticoagulants Management of the new antiplatelets and anticoagulants Session No.: 1 Name: C. Boustiere, T Ponchon Guidelines : Anti-thrombotic agents and digestive endoscopy 2006 : French guideline (SFED) 2007 : Japanese

More information

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University

More information

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9 Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer

More information

Provided by the American Venous Forum: veinforum.org

Provided by the American Venous Forum: veinforum.org CHAPTER 3 CLOTTING DISORDERS Original authors: Edith A. Nutescu, Jessica B. Michaud, Joseph A. Caprini, Louis W. Biegler, and Robert R. McCormick Abstracted by Kellie R. Brown Introduction The normal balance

More information

Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy

Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy Papers in Press. Published October 3, 2014 as doi:10.1373/clinchem.2014.226332 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2014.226332 Clinical Chemistry 60:12 000 000

More information

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY I. TREATMENT PLANNING GUIDELINES As part of informed consent, the clinician should carefully explain the risks and benefits of oral and maxillofacial surgery

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

Whole Blood Flow Cytometry

Whole Blood Flow Cytometry Whole Blood Flow Cytometry y Nailin Li Department t of Medicine, i Clinical i l Pharmacology Unit Karolinska Institute/University Hospital, 171 76 Stockholm Department of Pathology & Pathophysiology Zhejiang

More information

Review of Newer Antiplatelets, Antithrombotics and Reversal

Review of Newer Antiplatelets, Antithrombotics and Reversal Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine

More information

Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder

Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder Spring 2010 Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder INTRODUCTION: What is ITP? ITP, Immune Thrombocytopenic Purpura, is an acquired bleeding disorder in which the immune system

More information

Grade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.

Grade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer. Grade 4 Thrombocytopenia During Treatment with High-Dose IL-2 2 (HD IL-2) is a Predictor of Response in Melanoma but Not in Renal Cell Cancer. Timothy E. Bael, M.D. Bercedis L. Peterson, Ph.D. Karima Rasheed,

More information

Predictive power. Multiplate analyzer

Predictive power. Multiplate analyzer Predictive power Multiplate analyzer Multiplate analyzer Strengthening Roche s hemostasis portfolio With a series of industry firsts and innovative applications for early disease detection and monitoring,

More information

Indications 18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS

Indications 18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS 18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS Alan Tinmouth Platelets are the smallest of the blood cells, with a diameter of 2 3 µm and no nucleus. Their function

More information

The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing

The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing Ghislain Noumsi MD,SBB(ASCP) CM Molecular ImmunoHematologist Scientific Support Services LifeShare Blood Centers Shreveport, LA Objectives

More information

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06

More information

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs

More information

Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide

Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide Contents Smiling is the most beautiful way to show your teeth 3 What are the causes

More information

Is There A LIfe for DES after discontinuation of Clopidogrel

Is There A LIfe for DES after discontinuation of Clopidogrel Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:

More information

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW 1 Issues and Challenges in ACS Management Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW 2 Disclaimer Presentation are intended for educational purposes only and do not replace independent professional

More information

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs

More information

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix

More information

Connection March 2010

Connection March 2010 CCBD Connection March 2010 Results of 2009 Patient Satisfaction Survey Over the past year, CCBD social workers Jane Volkmann and Sheri Robbins conducted 412 face-to-face Patient Satisfaction Surveys with

More information

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES TABLE OF CONTENTS SUBJECT PAGE ADULT CRITERIA Red Blood Cells/Autologous 2 Washed Red Blood Cells 2 Cryoprecipitate

More information

Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps

Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management

More information

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h

More information

Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.

Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. Royal College of Surgeons in Ireland e-publications@rcsi Molecular and Cellular Therapeutics Articles Department of Molecular and Cellular Therapeutics --0 Dual antiplatelet therapy unmasks distinct platelet

More information

New Anticoagulants: When and Why Should I Use Them? Disclosures

New Anticoagulants: When and Why Should I Use Them? Disclosures Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia

More information

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000

More information

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran, rivaroxaban and apixaban and what are they used for?...2

More information

Genomic Analysis of Mature B-cell Malignancies

Genomic Analysis of Mature B-cell Malignancies Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:

More information

Abnormal Uterine Bleeding. Howard Herrell, MD FACOG

Abnormal Uterine Bleeding. Howard Herrell, MD FACOG Abnormal Uterine Bleeding Howard Herrell, MD FACOG Disclosures I, Howard Herrell, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a

More information

Guideline Statement for the Treatment of Disseminated Intravascular Coagulation

Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Introduction Though a rare occurrence in the perioperative setting, disseminated intravascular coagulation (DIC) is a syndrome

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Heparin Induced Thrombocytopenia

Heparin Induced Thrombocytopenia Heparin Induced Thrombocytopenia Ann-Marie Liberman B.Sc.Phm., ACPR Clinical Pharmacist, Cardiac Surgery Clinical Trials Pharmacist Royal Columbian Hospital Fraser Health Disclosure Participated in research

More information

Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009

Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009 Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009 Agenda Introduction Articles Poststreptococcal reactive arthritis in children: is it really a different entity from rheumatic fever? Poststreptococcal

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

University of Utah CME Statement

University of Utah CME Statement University of Utah CME Statement The University of Utah School of Medicine adheres to ACCME Standards regarding industry support of continuing medical education. Speakers are also expected to openly disclose

More information

Platelet function defects

Platelet function defects Haemophilia (2008), 14, 1240 1249 DOI: 10.1111/j.1365-2516.2008.01898.x ORIGINAL ARTICLE Platelet function defects D. SIMON,* T. KUNICKI and D. NUGENT* *From the ChildrenÕs Hospital of Orange County, Orange;

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Esther Lopez Garcia, Matthias B Schulze, Teresa T Fung, James B Meigs, Nader Rifai, JoAnn

More information

Periodontal Screening and Recording: Early Detection of Periodontal Diseases

Periodontal Screening and Recording: Early Detection of Periodontal Diseases Periodontal Screening and Recording: Early Detection of Periodontal Diseases Tanya Villalpando Mitchell, RDH, MS Continuing Education Units: 1 hour Online Course: www.dentalcare.com/en-us/dental-education/continuing-education/ce53/ce53.aspx

More information

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications

More information

Abnormal Basic Coagulation Testing Laboratory Testing Algorithms

Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Global Coagulation Testing Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Jeffrey S. Jhang, M.D. No single global laboratory test Bleeding history is the strongest predictor of bleeding

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

Now We Got Bad Blood: New Anticoagulant Reversal

Now We Got Bad Blood: New Anticoagulant Reversal Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies

More information

Per Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions

Per Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions Per Morten Sandset p.m.sandset@medisin.uio.no Hemostasis parameters and medication prior to radiological interventions The challenge Familial or acquired defects in the hemostatic system that dispose for

More information

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked

More information

Canine Distemper Virus

Canine Distemper Virus Canine Distemper Virus Canine Distemper (CD) is a highly contagious infectious disease of dogs worldwide caused by the canine distemper virus (CDV). It is often fatal. CD is a multisystemic disease that

More information

How To Know If You Have A Bleeding Disorder

How To Know If You Have A Bleeding Disorder WHAT ARE RARE CLOTTING FACTOR DEFICIENCIES? Published by the World Federation of Hemophilia (WFH) World Federation of Hemophilia, 2009 The WFH encourages redistribution of its publications for educational

More information

Foster, Gwendolyn Audrey. Short History of Film. : Rutgers University Press,. p 175 http://site.ebrary.com/id/10240595?ppg=175 Copyright Rutgers

Foster, Gwendolyn Audrey. Short History of Film. : Rutgers University Press,. p 175 http://site.ebrary.com/id/10240595?ppg=175 Copyright Rutgers : Rutgers University Press,. p 175 http://site.ebrary.com/id/10240595?ppg=175 : Rutgers University Press,. p 176 http://site.ebrary.com/id/10240595?ppg=176 : Rutgers University Press,. p 177 http://site.ebrary.com/id/10240595?ppg=177

More information

CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core

CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core Arlene Stecenko, MD Director, Emory + Children s Cystic Fibrosis Care Center

More information

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in

More information

Testing antiplatelet therapy

Testing antiplatelet therapy European Heart Journal Supplements (2008) 10 (Supplement A), A28 A34 doi:10.1093/eurheartj/sum081 Testing antiplatelet therapy Christian Gachet* and Boris Aleil INSERM U311 Unit, Etablissement Français

More information

Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital

Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital 1 Canada s Inherited Bleeding Disorder Centres 26 Hemophilia A, B

More information

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab) Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety

More information

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

New anticoagulants: Monitoring or not Monitoring? Not Monitoring The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and

More information

A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO

A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO review A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO Paula H. B. Bolton-Maggs, 1 Elizabeth A. Chalmers, 2 Peter W. Collins, 3 Paul Harrison, 4 Stephen

More information

Instructions for Use

Instructions for Use PN 14438.A.1 2012 09 14 Instructions for Use Technical Support: (US) 1 800 643 1640 (Outside US) +1 858 643 1600 MDSS: +1 858 643 1600 1 INTENDED USE The VerifyNow PRUTest is a whole blood test used in

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands Causes of Anemia in Patients with Heart Failure Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands Background Anemia is common in patients with CHF Prevalence 15 55%

More information

List of publications

List of publications List of publications List of publications List of publications L. van Bloemendaal & J.S. ten Kulve, S.E. la Fleur, R.G. IJzerman, M. Diamant. Effects of glucagonlike peptide 1 on appetite and body weight:

More information

Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women

Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Objectives Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Provide a framework to evaluate abnormal uterine bleeding (AUB) Review medical and surgical management options

More information

Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko

Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko Review Platelet function testing in clinical diagnostics A. R. Rechner Assay Development Hemostasis, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany Schattauer 2011 79 Keywords Platelet

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Introduction to Physical Evaluation. Part 2

Introduction to Physical Evaluation. Part 2 Introduction to Physical Evaluation Part 2 Medical History Patient must check off each box. No lines to be drawn down a column. Obtain additional info from patient on any yes answer. Make sure that you

More information